孟鲁司特钠联合布地奈德治疗支气管哮喘的临床疗效观察

Clinical observation of montelukast combined with budesonide in treatment of bronchial asthma

目的探讨孟鲁司特钠联合布地奈德治疗支气管哮喘的临床疗效。方法将200例支气管哮喘患者随机分成两组,每组各100例。两组均予抗生素抗感染、多索茶碱平喘,布地奈德1~2 mg加入生理盐水3 mL中雾化吸入,每天2次,症状缓解后可改为吸入0.5~1.0 mg/次,2次/d。观察组同时加用孟鲁司特咀嚼片口服10 mg/次,睡前服用,每天1次。疗程3个月。比较两组的临床疗效、肺功能及哮喘发作次数。结果观察组患者治疗后的总有效率为98.0%,明显高于对照组患者治疗后的70.0%(P<0.05)。观察组患者治疗后的哮喘发作次数为(1.17±0.20)次/d,显著低于治疗前及对照组(P<0.05)。观察组患者治疗后FEV1/FVC为(80.29±13.43),PEF为(87.25±11.32)%,均显著高于治疗前及对照组(P<0.05)。结论孟鲁司特钠联合布地奈德治疗支气管哮喘可以提高疗效,减少哮喘发作次数,改善肺功能,值得推广和应用。

Objective To investigate the clinical efficacy of montelukast combined with budesonide in the treatment of bronchial asthma. Methods A total of 200 cases of bronchial asthma patients were randomly divided into two groups, each group of 100 cases. Two groups were treated with antibiotics, doxofylline antiasthmatic; budesonide 1-2 mg in saline inhalation of 3 mL, 2 times a day, symptoms were changed after the inhalation of 0.5-1.0 mg/time, 2 times/d in- halation. The observation group was treated with montelukast chewable tablets orally 10 rag/times, before going to bed, every day for 1 time. Course of treatment for 3 months. The clinical efficacy, lung function and the number of asthma attacks were compared between the two groups. Results The total effective rate of the observation group was 98.0%, which was significantly higher than 70.0% of the control group after treatment （P〈O.05）. The number of asthma attacks in the observation group was （1.17±0.20） times/d, significantly lower than that before treatment and control group （P〈 0.05）. The FEV1/FVC of the patients in the observation group was（80.29±13.43）, the PEF was（87.25±11.32）%, signifi- cantly higher than that before treatment and control group （P〈0.05）. Conclusion Montelukast sodium combined with budesonide in the treatmem of bronchial asthma can improve the efficacy, reduce the number of asthma attacks, improve lung function, it is worthy of promotion and application.